Publication | Open Access

Phase I/II study of a combination of capecitabine, cisplatin, and intraperitoneal docetaxel (XP ID) in advanced gastric cancer patients with peritoneal metastasis

Gastrointestinal OncologyPhase I/ii StudyMedicineXp IdIntraperitoneal DocetaxelPathologyCancer TreatmentOncologyRadiation OncologyCancer Research